CoverDiscovery on Target is CHI’s premier Drug Discovery event that brings to light the latest developments in the science and technologies underlying cellular pathways and drug targets. In its seventh year of production Discovery on Target, covers a diverse set of topics and captures an international audience spanning both industry and academia. This year, the event comprised of seven conference programs showcasing novel targets and approaches for research in ion channels, diabetes, kinases, G-protein coupled receptors, histone deacetylases and for RNA Interference-based screening tools and therapeutics.    Read more > 

Concurrent Tracks
November 2-3, 2009

Concurrent Tracks
November 3-4, 2009


Clapham David David Clapham, M.D., Ph.D.,
Howard Hughes Medical Institute

Dabrowski Michael Michael Dabrowski, Ph.D.,

Gregory J. Kaczorowski Gregory J. Kaczorowski,
School; Robert Wood Johnson Medical School

John Maraganore John M. Maraganore, Ph.D.,
Alnylam Pharmaceuticals, Inc.

Graeme Milligan, Ph.D Graeme Milligan, Ph.D.,
University of Glasgow

Steve Nissen Steven E. Nissen, M.D.,
M.A.C.C., Cleveland Clinic Foundation

David Root, Ph.D.,
The RNAi Consortium Broad Institute of MIT and Harvard

Anja J. Stauber, Ph.D., DABT,
Eli Lilly and Company

Eric M. Verdin, M.D.,
University of California, San Francisco
DOT Hub Icon 

 Short Courses

2015 Discovery on Target Brochure  





Molecular Sensing

Rosa Drug Development Advisors






The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager


September 21 

Next-Generation Histone Deacetylase Inhibitors Symposia 

Strategies for Rare Diseases Symposia 

September 22 

Developing CRISPR-Based Therapies Symposia 

September 22 - 23 

Targeting Epigenetic Readers and Chromatin Remodelers 

Targeting the Ubiquitin Proteasome System 

Targeting the Microbiome 

GPCR - Based Drug Discovery - Part 1 

Antibodies Against Membrane Protein Targets - Part 1 

RNAi for Functional Genomics Screening 

Gene Therapy Breakthroughs 

Targeting Ocular Disorders 

September 23 - 24 

Targeting Histone Methyltransferases and Demethylases 

Targeting the Unfolded Protein Response 

Kinase Inhibitor Discovery 

GPCR-Based Drug Discovery - Part 2 

Antibodies Against Membrane Protein Targets - Part 2 

New Frontiers in Gene Editing 

Quantitative Systems Pharmacology 

Short Courses 

SC1: Cancer Metabolism: Pathways, Targets and Clinical Updates 

SC2: Leveraging Data and Analytics for Drug DiSCovery 

SC3: Setting Up Effective Rnai SCreens: From Design to Data to Validation 

SC4: Phenotypic SCreening and Chemical Probe Development 

SC5: GPCR Structure-based Drug Discovery 

SC6: Targeting of GPCRs with Monoclonal Antibodies 

SC7: Setting Up Effective Functional SCreens Using 3D Cell Cultures 

SC8: Targeting Protein-protein Interactions: Biophysical Approaches 

SC9: Preclinical Animal Models for Ocular Indications 

SC10: Introduction to Allosteric Modulators and Biased Ligands of GPCRs 

SC11: Introduction to Targeted Covalent Inhibitors 

SC12: Assays and High-throughput SCreening for Novel Epigenetic Inhibitors 

SC13: Gamification and Drug Target Challenges 

SC14: A Primer to Gene Editing: Tools and Applications 

SC15: Using Mechanistic Physiological Models In Drug Development